Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

rate, the Company has proposed an amended trial to continue its interest in the relapsed setting.

An agreement has been reached with the FDA on modifications to Vion Study CLI-037. The revised study includes a lower dose of Cloretazine(R) (VNP40101M) in the experimental arm of the trial and prophylactic therapy with antibiotics, antifungals and growth factors for all patients. In order to maintain the Special Protocol Assessment (SPA) with the FDA for this trial, the next step is to submit an SPA to the FDA with these modifications before recommencing the trial.

Dr. Frank Giles, Chief of the Division of Hematology and Medical Oncology at the University of Texas Health Science Center at San Antonio, and lead investigator on the Cloretazine(R) clinical program stated, "Cloretazine(R) has recently shown very significant single agent activity in a the difficult to treat elderly AML patient population. It is important that we now establish the optimal dosing schedule in combination with other chemotherapeutic agents, such as cytarabine." He concluded, "Modifications to this Phase III trial in patients with relapsed AML will allow us to examine a combination schedule that should maintain the activity observed in the initial portion of the study with an acceptable marrow toxicity profile."

The Company also announced plans to file an abstract on data from Vion Study CLI-037 for the Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in June 2008.

Ann Cahill, Vice President, Clinical Development, commented, "Cloretazine(R) (VNP40101M) is an active agent in AML, and we continue to believe that it will have clinical utility in both the frontline and second line settings, as either a single agent or in combination with other therapies."

The Company has announced previously that it plans to file a New Drug Application with the FDA in 2008 based on a pivotal Phase II study of Cloretazine(R) (VNP40101M) as a single agent in eld
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in Boston.  The public is welcome to participate ... Array BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: ... 10, 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
(Date:9/2/2015)... , Sept. 2, 2015 ... revenue base with highly profitable specialty products ... Near-term growth potential with 11 product applications pending ... IV certifications  , Provides medium and longer ... development, including eight controlled substances , Adds ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ... Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... provide a detailed overview of the key areas of pharmaceutical ... Hong Kong , Macau and ... - All important aspects of gaining and maintaining a ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... today announced the,publication of the results from a ... cruciate ligament (ACL) reconstruction,surgery. OMS103HP is an investigational ... and is designed to improve postoperative,knee function and ... return to work. The article titled "Novel Drug ...
... PHILADELPHIA, Aug. 25 Scientists have,discovered gene mutations ... the childhood cancer neuroblastoma. In addition, the researchers found,that ... forms of,non-inherited neuroblastoma, the more common form of the ... first genetic tests to families,affected by the inherited form ...
Cached Medicine Technology:Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4
(Date:9/3/2015)... ... September 03, 2015 , ... The new ... Report of Provo, Utah. The Clinicians Report is a leading information source to ... located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for ...
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 ... had great success in launching their Path11 Podcast with 23 episodes released since April ... is the well known Spiritual Catalyst and Linda Howe, leader in the field of ...
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership ... customer and technical support services to promote LodonalTM in Nigeria. The distribution will ... the efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, ...
(Date:9/2/2015)... ... ... One can hardly argue against the fact that more and more people are using ... are being used as GPS, to make purchases, and yes, even to find a ... can now join the prestigious social ranks of e-dating. , Recently, Mr. Josh ...
(Date:9/2/2015)... Poulsbo, WA (PRWEB) , ... September 02, 2015 , ... ... store, open September 2015. “It was a simple decision, really,” says Chris. “We have ... shop here. They know the brands that work best for them—so we’ve given them ...
Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2
... are worried, as the floodplains of the Yamuna river are ... and even hotels for the 2010 Commonwealth Games. ... danger for the city's water security, they warn. ... weekend at Rajghat in New Delhi. It is being organized ...
... Taser to control agitated suspects in police custody is ... In some circles, however, the idea that using a ... controversy. ,Now, the final results of a ... of California, San Diego (UCSD) Medical Center showed no ...
... on black silk. The imagery is powerful and the prospect ... have turned to cocaine in a big way, throwing ... for instance, once hailed as a brilliant advocate, is ... naked and unconscious last Friday in a hotel room by ...
... positive effect on someones physical health? This question is ... of the latest Medical Journal of Australia. ... and spirituality in health, its relevance to Australian practitioners ... practice, and the current gaps where more research is ...
... hydropower projects being clean, a new scientific study has ... for at least 19 percent of India's global ... study, Indian dams are larger methane emitters and total ... around 33.5 million tonnes (MT) per annum, including emissions ...
... in the mouth like a popular breath-freshener could someday ... The innovative drug-delivery system was developed by Johns ... two-semester course, the seven-student team fabricated a thin film ... the child to swallow the vaccine. The dissolved medication ...
Cached Medicine News:Health News:Green Campaigners Concerned About Yamuna's Shrinking Floodplains 2Health News:Healthy Humans Not Harmed By Taser 2Health News:Australia Agonising Over the Problem of Cocaine Use by Lawyers 2Health News:Australia Agonising Over the Problem of Cocaine Use by Lawyers 3Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 2Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 3
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: